circRNA & saRNA Synthesis Market (2026-2036)

The growth of this market is driven by the emergence of two next-generation RNA modalities, circular RNA and self-amplifying RNA, that address fundamental limitations of conventional linear mRNA therapeutics in durability of protein expression, dose efficiency, and manufacturing economics. Circular RNA is a covalently closed RNA molecule with no free 5' or 3' ends, which confers exceptional resistance to exonucleolytic degradation and extends intracellular half-life substantially beyond that of linear mRNA. Self-amplifying RNA is an engineered RNA molecule derived from alphavirus genomes that incorporates the viral RNA-dependent RNA polymerase machinery, enabling the molecule to self-replicate within the transfected cell and sustain high-level antigen or protein expression from a fraction of the dose required for conventional mRNA. Both modalities are attracting significant scientific and commercial interest as platforms for vaccines, gene therapy, protein replacement, and cancer immunotherapy, and the synthesis, purification, and formulation technologies required to produce them at clinical and commercial quality define the circRNA and saRNA synthesis market.

The broader RNA therapeutics landscape provides the commercial context for this emerging market. According to a peer-reviewed review published in PubMed Central (Cell Reports Medicine, May 2024), as of 2024 there were 17 FDA-approved RNA therapeutics and more than 222 ongoing clinical trials of RNA-based medicines across antisense oligonucleotides, siRNA, mRNA, and emerging modalities. The first FDA-approved RNA therapeutics dates to 1998 with fomivirsen, and the class has grown substantially over the subsequent decades, culminating in the approval of mRNA COVID-19 vaccines from Pfizer-BioNTech and Moderna under the Emergency Use Authorization in 2020 and full approval as Comirnaty and Spikevax in 2022. This established regulatory and clinical infrastructure for RNA therapeutics provides the commercial and scientific foundation on which circRNA and saRNA synthesis technologies are being built and commercialized.

The circRNA and saRNA synthesis market is defined by the technologies, reagents, equipment, and services used to produce two structurally distinct next-generation RNA modalities at the quality required for research, clinical, and ultimately commercial application. Circular RNA is produced through a synthesis workflow that begins with the design and production of a DNA template encoding the desired RNA sequence with splice sites or ribozyme sequences flanking the region to be circularized. The template is transcribed by in vitro transcription to produce a linear RNA precursor, which is then circularized through one of several chemical or enzymatic approaches including splint-mediated ligation using T4 RNA ligase, group I or group II intron-based self-splicing, chemical phosphoramidite ligation, or the use of the permuted group I ribozyme system developed by researchers at the Wesselhoeft laboratory and widely adopted in the field. The circularized product is then purified by HPLC or denaturing gel electrophoresis to remove residual linear precursors, characterized by analytical methods including gel electrophoresis, mass spectrometry, and RNase R treatment, and formulated in lipid nanoparticles or other delivery vehicles for in vivo application.

Self-amplifying RNA is produced by in vitro transcription of a DNA template encoding both the alphavirus non-structural protein replicase complex, most commonly derived from Venezuelan Equine Encephalitis Virus or Sindbis virus, and the therapeutic antigen or protein of interest. The resulting saRNA molecule is substantially larger than conventional mRNA, typically 9,000 to 12,000 nucleotides compared with 1,000 to 4,000 for linear mRNA vaccines, which presents unique challenges for IVT yield, purification, and quality control. Because saRNA molecules self-amplify within transfected cells through the action of the encoded replicase, the effective dose required to achieve a given level of protein expression is substantially lower than for conventional mRNA, enabling dose reduction of 10-fold to 100-fold compared with equivalent linear mRNA constructs. The ARCT-154 saRNA COVID-19 vaccine, which received the world's first regulatory approval for a saRNA vaccine from Japan's Pharmaceuticals and Medical Devices Agency on November 27, 2023, and began real-world distribution in Japan in October 2024, contains 100 micrograms of saRNA per dose, a dose that demonstrates the self-amplifying mechanism enabling meaningful immunological response from a relatively low RNA mass.

The competitive landscape of the circRNA and saRNA synthesis market spans RNA therapeutics developers who own the proprietary platforms, reagent and enzyme suppliers that provide the IVT systems and circularization kits, CDMO organizations that provide synthesis services, and analytical and formulation technology companies. Arcturus Therapeutics is the most clinically advanced saRNA developer, with ARCT-154 already approved and distributed in Japan. Moderna and BioNTech, leveraging their established mRNA manufacturing infrastructure, are active in next-generation RNA formats including saRNA. CureVac has saRNA programs in its pipeline. In the circRNA space, Orna Therapeutics, Laronde, and Circular Genomics are among the companies advancing circRNA expression platforms toward clinical programs. On the synthesis technology and services side, TriLink BioTechnologies, Aldevron, Maravai LifeSciences, and WuXi AppTec provide IVT reagents, custom RNA synthesis, and GMP manufacturing services that support the circRNA and saRNA development ecosystem.